Adicet bio highlights preclinical data supporting ind readiness for adi-270 in an oral presentation at the american society of gene and cell therapy (asgct) 27th annual meeting

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting adi-270, an armored allogeneic “off-the-shelf” gamma delta car (chimeric antigen receptor) t cell therapy candidate targeting cd70 positive cancers, has been selected for an oral presentation at the.
ACET Ratings Summary
ACET Quant Ranking